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A
 
BSTRACT
 
Allergen-specific immunotherapy (SIT) involves the
administration of gradually increasing amounts of an
allergen extract to reduce clinical symptoms of allergy.
Well-controlled clinical trials have demonstrated the
efficacy of SIT in the treatment of allergic diseases,
including rhinoconjunctivitis and asthma, and best
practice protocols have been established. Neverthe-
less, application of this potentially curative treatment is
restricted, largely due to the risk of serious adverse
events, especially in asthmatics. Although efficacy is
high for venom-induced allergy, success rates for the
more common aeroallergen-induced disease range
from 60 to 80% depending on the allergen. The prac-
tice of SIT is currently being refined following major
advances in our knowledge of basic immune mecha-
nisms. In particular, new T cell-targeted strategies are
being explored with the awareness of the pivotal role
allergen-specific T cells play in initiating and regulat-
ing the immune response to allergens. Current SIT
induces decreased IgE class switching and eosinophil
activation by downregulating production of the
T helper (Th) 2-type cytokines interleukin (IL)-4 and
IL-5. Therefore, allergen preparations that have
ablated IgE binding while retaining T cell reactivity
should still be clinically effective but have substantially
improved safety. These approaches include the use of
small peptides based on dominant T cell epitopes of
allergens and chemically modified or recombinant
allergen molecules. Both approaches have already
been tested, with promising results, in animal models;
peptide immunotherapy has been shown effective in
clinical trials. Defined hypoallergenic molecules or
peptides offer ease of standardization in addition to
efficacy and safety and will result in more widespread
use of SIT in clinical practice. Elucidation of mecha-
nisms for downregulating Th2-predominant responses
to allergen by SIT will enable the development of lab-
oratory assays for monitoring clinical efficacy.
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I
 
NTRODUCTION
 
Allergic diseases, including asthma, rhinitis/conjunctivitis
and eczema, are common and are estimated to affect
up to one-quarter of the population in developed
countries at some time in their lives. The allergic
diseases are a class of disorders that result from inter-
actions between an inherited genetic predisposition
and the local environment. Allergy may be defined as
an aberrant immune-mediated response to commonly
encountered substances that are otherwise harmless.
Allergic diseases mainly affect atopic individuals, who
synthesize specific IgE to common environmental aller-
gens, usually proteins or glycoproteins. These include
allergens of house dust mites (HDM), grass, tree and
weed pollens, domestic pets (cats and dogs) and various
molds. The major perennial allergens are from HDM
and cats, with pollens forming the main sources of
seasonal allergens.
Immunoglobulin E is the main specific effector mole-
cule in the immune response to allergens. Re-exposure
to the relevant allergen of sensitized skin or airways of
atopic subjects may induce a biphasic response, with an
immediate hypersensitivity and a delayed inflammatory
component. Allergen can cross-link specific IgE bound to
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high-affinity IgE receptors (Fc
 
∈
 
RI) on the surface of mast
cells or basophils, inducing calcium flux and the subse-
quent release of inflammatory and vasoactive mediators,
including histamine, leukotrienes and cytokines. The late-
phase response predominantly results from sustained
effects of mediators such as prostaglandins, leukotrienes
(LT) B
 
4
 
, LTC
 
4
 
 and platelet-activating factor released from
the recruited cellular infiltrate of eosinophils, neutrophils,
macrophages and lymphocytes (for review see Kay
 
1
 
).
The CD4
 
+
 
 T cells play a central role in orchestrating
the immune response to allergen. The peripheral CD4
 
+
 
T cell repertoire of both atopic and non-atopic individ-
uals includes recognition of allergens, but the nature of
the immune response differs between atopic and non-
atopic subjects.
 
2
 
 Allergen is initially taken up by antigen-
presenting cells (dendritic cells, monocytes/macrophages,
B cells), processed and presented as peptides to specific
antigen receptors on the T cell surface in association with
major histocompatibility complex (MHC) class II mole-
cules. In atopic individuals, the activated allergen-
specific T cell secretes a T helper (Th) 2-type cytokine pro-
file, dominated by interleukin (IL)-4, IL-5 and IL-13, and
these cytokines, together with cognate B and T lym-
phocyte interactions, result in immunoglobulin class
switching with specific IgE synthesis by B cells. In contrast,
activated allergen-specific T cells from non-atopic sub-
jects elaborate a Th1-type cytokine profile with dominant
interferon (IFN)-
 
γ
 
 secretion. The nature of the immune
response is determined by factors including the genotype
of the individual, antigen form and concentration, the
antigen-presenting cell and the local cytokine milieu.
Conventional treatment for allergic diseases is prim-
arily the use of non-specific pharmacotherapy, including
antihistamines, 
 
β
 
2
 
-adrenergic receptor agonists, leuko-
triene receptor antagonists, corticosteroids and, occa-
sionally, epinephrine for symptomatic relief, and specific
therapy targeting the underlying disease process.
 
3
 
Specific therapies include allergen avoidance where
feasible and allergen-specific immunotherapy (SIT). A
clear demonstration of symptoms on exposure to the
offending allergen with documentation of allergen-specific
IgE is required for recommendation of specific therapies.
Allergen-specific immunotherapy has been used in
clinical practice since 1911, when it was pioneered by
Noon
 
4
 
 and Freeman.
 
5
 
 Conventional SIT involves vacci-
nation with increasing subcutaneous quantities of aller-
gen in order to hyposensitize the patient and achieve both
immunologic and physiologic tolerance on subsequent
allergen re-exposure. Allergen-specific immunotherapy is
an attractive treatment option because it may alter the
natural course of allergic disease. Controlled trials have
demonstrated efficacy for stinging insect allergy, allergic
rhinitis/conjunctivitis and allergic asthma in appropriately
selected patients.
 
6
 
 Research in children has shown that
SIT may prevent the development of new sensitivities in
monosensitized patients
 
7,8
 
 or the progression to asthma
in patients with allergic rhinitis.
 
9,10
 
 Currently, immuno-
therapy with unfractionated extracts of natural rubber
latex and foods such as peanuts and shellfish has proved
unsatisfactory due to the high risk of systemic adverse
events and is used only for research studies. Elucidation
of underlying mechanisms of SIT and of relevant antigen
preparations for efficacy is required to develop more
widespread use of SIT in routine clinical practice.
 
A
 
LLERGEN
 
-
 
SPECIFIC
 
 
 
IMMUNOTHERAPY
 
: 
C
 
URRENT
 
 
 
STRATEGIES
 
Allergen preparations and therapeutic 
regimens
 
The majority of allergenic extracts in current use for
SIT are unfractionated alum-precipitated preparations
with delayed allergen absorption to reduce adverse
events particularly associated with IgE-mediated mast
cell and basophil degranulation. Aqueous allergen
extracts are available with higher potency due to more
rapid absorption and a concomitantly higher risk of
adverse events.
Allergen extract standardization is increasingly empha-
sized to improve the overall clinical efficacy of SIT with
determination of total allergenic proteins and biological
activity. Traditional unfractionated extracts were charac-
terized to a biological standard ‘Bioequivalent Allergy
Units’ by correlation of skin test potency compared
with histamine controls using a known panel of highly
sensitized subjects. However, alum-precipitated extracts
cannot be accurately standardized by these methods.
With the availability of improved biochemical and molec-
ular immunologic techniques, including the generation of
allergen-specific monoclonal antibodies, more impor-
tance is now placed on quantitation of the dominant
allergens in therapeutic extracts; for example, measure-
ment of the Der p 1 concentration in an HDM 
 
Derma-
tophagoides pteronyssinus
 
 extract. Clinical studies have
clearly demonstrated that mixtures of unrelated allergens
may be less efficacious.
 
11
 
 Well-characterized allergen
extracts of known potency and shelf life are recommended
for both effective diagnosis and treatment regimens in
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accordance with the guidelines of the World Health
Organization.
 
6
 
Traditionally, SIT involves the administration of incre-
mental doses of allergen extract in an initial up-dosing
regimen followed by maintenance treatment (reviewed by
Rolland 
 
et al
 
.
 
12
 
). The subcutaneous route is still the most
commonly used, although sublingual therapy is increas-
ingly popular in central Europe.
 
13
 
 The different dosage
schedules include standard, rush and ultra-rush regimens.
Standard SIT involves weekly or two-weekly injections
during the up-dosing induction phase, followed by main-
tenance injections at increasing intervals as tolerated,
usually up to monthly intervals. Typically, subcutaneous
injections are administered into the soft tissue of the
upper lateral arm followed by a 45 min observation
period in case of an adverse event. Rush immunotherapy
over, perhaps, 5 days and ultra-rush immunotherapy
over 1 day may be used in hospital-based allergy units
with more rapid dose escalations at 30–60 min intervals.
The immediate availability of epinephrine and adequate
cardiorespiratory resuscitation facilities to treat anaphy-
laxis if necessary are mandatory if SIT is offered to
patients as a treatment option.
 
Clinical efficacy
 
Immunotherapy for allergic disease is of proven efficacy
for allergic rhinitis/conjunctivitis and for insect venom
allergy. In contrast, although meta-analyses have dem-
onstrated efficacy of SIT in asthma for HDM allergy,
 
14
 
the role of SIT for the treatment of asthma remains
controversial with regard to adverse events, cost-benefits
and efficacy. Insect venom allergy resulting in systemic
allergic reactions is an absolute indication for SIT,
with respiratory allergies providing a relative indication
depending on the clinical history of the individual patient
and the offending allergen.
Efficacy is judged on the basis of subjective and objec-
tive outcomes. Symptom and medication scores can be
monitored by diarization for comparison between thera-
peutic modalities. Numerous controlled studies demon-
strate high efficacy in insect venom hypersensitivity.
 
15
 
Similarly, the efficacy of SIT in seasonal allergic rhinitis is
well established.
 
16
 
 A meta-analysis of clinical trials of
HDM SIT in selected asthmatic populations reported
efficacy
 
17
 
 and a recent Cochrane’s analysis again dem-
onstrated improvement in symptoms and bronchial
reactivity to allergen, but no objective improvement in
lung function was determined.
 
14
 
 Efficacy of SIT using a
standardized cat dander extract has also been reported.
 
18
 
IgE-mediated side-effects of immunotherapy
 
Local reactions to conventional SIT for inhalant aller-
gens or venom occur in 25% of patients, but are not
a contraindication to therapy. Large local reactions
(> 5 cm) require a dosage reduction. The estimated
frequency of systemic adverse events is one event per
500 injections.
 
19
 
 Typically, such reactions occur within
15–20 min, although they may occur up to 45 min
after dosage administration. Deaths are infrequent and
almost invariably follow a departure from recommended
best practice, in particular by delayed treatment of
anaphylaxis.
 
Laboratory assays for monitoring efficacy of 
immunotherapy
 
Currently, there are no approved laboratory assays for
monitoring the clinical efficacy of SIT and treatment
regimens are largely empiric. Specific IgE levels assayed
by skin prick tests and radioallergosorbent test (RAST)
are useful in the diagnosis of allergic disease but, as
will be discussed further in the present review, are
not reliable indicators of clinical improvement. Suitable
assays for monitoring SIT will develop from a greater
understanding of the underlying mechanisms of clinically
effective SIT.
 
P
 
ROPOSED
 
 
 
MECHANISMS
 
 
 
OF
 
 
 
CLINICALLY
 
 
 
EFFECTIVE
 
 
 
ALLERGEN
 
 SIT
 
Many different regimens with respect to the allergen
(inhalant or venom), route of administration, allergen
form and concentration, adjuvant, dosing interval and
duration of therapy are currently in clinical use for
allergen SIT with probable differing mechanisms of
action. Immunologic studies investigating the mecha-
nisms of effective immunotherapy following parenteral
administration of allergen in the human model are
limited. The majority of the available data has been
derived from evaluation of SIT given via the sub-
cutaneous route, although increasing interest is focusing
on sublingual and intranasal routes of administration,
with efficacy reported in double-blind, placebo-
controlled studies.
Because allergen-specific IgE antibodies are the hall-
mark of the immune response to allergens, early studies
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investigating the mechanisms of SIT focused on changes
in allergen-specific antibodies. Characteristically, allergen-
specific IgE antibody levels increase initially, followed by
a decrease several months or years after treatment and
with poor correlation to the overall clinical efficacy.
 
20–22
 
These changes in specific IgE are accompanied by
increases in allergen-specific IgG1 and IgG4 antibody
subclasses, which have been suggested to act as ‘block-
ing’ antibodies, but, again, there has been poor correla-
tion between the timing of these changes and of clinical
efficacy.
 
23,24
 
 It was suggested that IgG1 and IgG4 anti-
bodies compete with IgE for binding sites on the aller-
gens, with the net result of preventing allergen-induced
activation of basophils and mast cells and consequent
prevention of the release of inflammatory mediators.
 
25
 
However, more recent studies have suggested that these
blocking antibodies may play a role by the prevention of
CD4
 
+
 
 T cell activation mediated by serum IgE-facilitated
allergen presentation.
 
26
 
 Prior to SIT, allergen-specific
IgE facilitates antigen presentation to CD4
 
+
 
 T cells via
CD23, the low-affinity IgE receptor, with activation in
response to even very low allergen concentrations. Post-
SIT, in the presence of increased levels of allergen-
specific IgG, there is a requirement for much higher aller-
gen concentrations in order to induce T cell activation.
Allergen-specific immunotherapy reduces both early
and late-phase responses to allergen challenge, con-
sistent with reduced inflammatory cell activity. There
are reports of reduced recruitment of eosinophils into
challenge sites following SIT
 
27
 
 and of reduced release
of inflammatory mediators, such as eosinophil cationic
protein and platelet-activating factor.
 
28,29
 
 Changes in the
allergen-induced cytokine profile of cells in the nasal
mucosa are also seen after SIT: increased expression of
mRNA for IFN-
 
γ
 
 and IL-12 has been reported following
grass pollen immunotherapy.
 
30
 
Recent studies investigating immunologic mechanisms
of SIT demonstrate convincingly that altered T cell
function correlates well with clinically efficacious SIT
(reviewed by Rolland and O’Hehir
 
31
 
 and Akdis and
Blaser
 
32
 
). Allergen-specific inhibition of T cell prolifera-
tion is observed with a trend to decreased secretion of
both Th1 and Th2 cytokines. Overall, however, there
tends to be a decrease in the ratio of IL4/5 to IFN-
 
γ
 
 levels
more typical of a non-atopic subject. The changes in the
prototypic Th1 and Th2 cytokines are accompanied by
increased CD25 surface expression on the T cells and
enhanced IL-10 production
 
33,34
 
 and IL-12 signaling from
antigen-presenting cells.
 
35
 
 With improved assay sensitivity
to allow whole blood sampling, assays of T cell cytokine
changes during SIT may provide future laboratory options
for objectively monitoring the efficacy of SIT.
 
A
 
LTERED
 
 T 
 
CELL
 
 
 
FUNCTION
 
 
 
FOLLOWING
 
 SIT
 
It is now clear that the nature and degree of the T cell
response to environmental allergen determines whether
clinical tolerance or a pathological antibody and inflam-
matory cell response ensues. The observed changes in
allergen-specific antibody levels and inflammatory cell
activity following clinically effective SIT can be accounted
for by the decreased T cell proliferative and cytokine
response to allergen with a shift from a predominantly
Th2- to a Th1-type profile. Elucidation of the mecha-
nisms by which T cell function is altered by allergen
immunotherapy will permit refinement in allergen
administration regimens to more effectively achieve this
change. Proposed mechanisms include anergy or dele-
tion of allergen-specific Th2 cells, immune deviation and
expansion of a regulatory cell subset.
 
Anergy
 
T cell anergy is defined as the antigen-induced induction
of specific non-responsiveness to subsequent challenge
with immunogenic concentrations of antigen.
 
36
 
 That
T cells have been silenced and not deleted can be
demonstrated by a proliferative response to IL-2. 
 
In vitro
 
models have demonstrated that T cell anergy can be
induced by treatment with high doses of antigen in the
form of dominant epitope peptides
 
36
 
 or antigen stimula-
tion in the absence of antigen-presenting cells (i.e.
costimulation).
 
37
 
 T cell anergy as a mechanism for
altered T cell function with SIT is feasible because doses
of allergen given in immunotherapy regimens are esti-
mated to be considerably higher than those encountered
naturally. However, precise measurement of relevant
environmental allergen levels is difficult.
 
38
 
 Allergen is
also usually administered by subcutaneous injection
rather than via the mucosal route, as for natural allergen
exposure, resulting in a different type and activation
state of antigen-presenting cell. Thus, both high allergen
dose and altered antigen presentation could predispose
to anergy induction by immunotherapy.
Clear evidence for anergy induction from clinical
studies of immunotherapy is difficult to obtain due to the
polyclonal nature of the analyzed T cell populations.
However, studies by Akdis 
 
et al
 
. point to T cell anergy as
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an important mechanism for a decreased Th2-type
response following bee venom immunotherapy.
 
39
 
 After
2 months treatment, patients showed a marked decrease
in T cell proliferative response to the major bee venom
allergen phospholipase A
 
2
 
 (PLA
 
2
 
). Production of IL-4,
IL-5 and IL-13, as well as IL-2 and IFN-
 
γ
 
, by allergen-
stimulated T cells was also reduced. There was no
change in response to control antigens purified protein
derivative and tetanus toxoid, demonstrating antigen
specificity of the immunotherapy. Further evidence for
induction of specific anergy in allergen-reactive T cells
was the almost complete recovery of the allergen-
induced proliferative response when IL-2 or IL-15 was
added to the 
 
in vitro
 
 cultures.
Increased IL-10 production was shown to parallel
decreased proliferative response to PLA
 
2
 
 following bee
venom immunotherapy in these patients and the addition
of neutralizing anti-IL-10 antibody to cultures could
reconstitute the proliferative and cytokine response.
 
33
 
In a similar study on insect venom immunotherapy,
Bellinghausen 
 
et al
 
.
 
34
 
 found an increased number of
IL-10-producing cells in peripheral blood after treatment
and a decreased number of IL-4-producing cells. Addi-
tion of blocking anti-IL10 antibodies to cultures restored
proliferative responses to allergen and enhanced allergen-
induced IFN-
 
γ
 
 production. It has been suggested that
elucidation of factors that influence the production of
regulatory IL-10 and, thus, induction of specific anergy
and the production of local IL-2 for subsequent reactiva-
tion of anergized T cells to a Th1-biased pathway will be
pivotal to the development of improved immunotherapy
strategies.
 
40
Apoptosis
 
The decreased proliferative response to allergen follow-
ing immunotherapy may also be accounted for by
deletion or apoptosis of allergen-specific T cells. Activation-
induced cell death by apoptosis is a recognized mecha-
nism for T cell homeostasis and may follow repeated
high-dose antigen stimulation in the periphery.
 
41
 
 There-
fore, apoptosis of allergen-specific T cells may be
expected to be a mechanism by which allergen immuno-
therapy downregulates the pathogenic Th2 response to
allergen. It is difficult to demonstrate induction of apop-
tosis 
 
in vivo
 
, but analysis of blood lymphocyte suscep-
tibility to apoptosis following allergen restimulation in
culture has provided one approach. In a study of rye
grass- and olive tree pollen-sensitive patients treated
with specific immunotherapy, apoptosis of blood lym-
phocytes after 4 days of culture with allergen was
shown to be increased compared with a control
untreated patient group using Annexin-V staining and
flow cytometric analysis.
 
42
 
 In a subsequent study,
dual terminal deoxyribonucleotidyl transferase-mediated
dUTP–digoxigenin nick end-labeling (TUNEL) and intra-
cellular cytokine staining revealed preferential apoptosis
of Th2-type cells after immunotherapy.
 
43
 
 Interestingly, in
a study of mitogen-treated peripheral blood T cells,
those cells that had been anergized were more suscep-
tible to Fas-mediated apoptosis,
 
44
 
 suggesting that anergy
and apoptosis may act in concert during immuno-
therapy.
 
Immune deviation
 
Whether a committed T cell can change from predomi-
nant Th2 cytokine production to Th1 is controversial.
Nevertheless, model systems using allergen-specific T cell
clones provide a precedent for such ‘immune deviation’.
Pretreatment of a HDM allergen-specific T cell clone
with a high dose of specific peptide not only induced a
markedly decreased proliferative response to an immu-
nogenic concentration of allergen, but also altered the
cytokine profile on rechallenge.
 
45
 
 Secretion of IL-4 could
not be detected, whereas IFN-
 
γ
 
 production was uninhib-
ited. In another model, a dose-dependent skewing of
cytokine profile of PLA
 
2
 
-specific T cell clones was dem-
onstrated; higher doses favored IFN-
 
γ
 
 production over
IL-4.
 
46
 
 While clinical studies consistently show decreased
Th2-type cytokine profiles accompany effective immuno-
therapy, IFN-γ production has been reported to increase,
be unchanged or decrease depending on the allergen
(reviewed by Rolland and O’Hehir31). Whether there is
altered cytokine production by committed Th2-type cells,
expansion of Th1 cells or differentiation of Thp/Th0-type
cells to Th1 is not clear. Several factors may influence
whether naïve allergen-specific T cells differentiate into
polarized Th1- or Th2-type cytokine positive cells.47
During allergen immunotherapy, high antigen dose will
favor the induction of local Th1-type cytokines and, thus,
expansion of committed Th1 cells and differentiation of
naïve T cells to the Th1 type. However, to date, only
limited cytokine panels have been evaluated in most
studies and there is ample evidence from model studies
that antigen-induced changes in cytokine profiles may
be more complex than simply skewing from the Th2 to
the Th1 type.
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Regulatory cells
Evidence for the induction of antigen-specific suppres-
sor cells by allergen immunotherapy was presented as
early as 1980.48 However, the role of CD8+ T cells in
mediating clinical tolerance to allergens by production
of IFN-γ remains controversial. In animal models,
IFN-γ-producing CD8+ cells have been implicated.49
By producing IFN-γ, such a subset could inhibit the
Th2 cell proliferative response to allergen and skew
the cytokine profile of allergen-specific cells. Interest-
ingly, when human peripheral blood cells from atopic
donors are stimulated repeatedly with a high concen-
tration of allergen in culture for 2 weeks, there is
expansion of not only CD4+ IFN-γ-positive cells, but
also CD8+ IFN-γ-positive cells (LM Gardner, unpubl.
obs., 2002). Of note is the fact that despite increased
production of IFN-γ by CD4+ and, possibly, CD8+
cells following immunotherapy, patients do not experi-
ence cell-mediated pathology at sites of allergen
encounter. This observation may be explained by the
simultaneous production of the anti-inflammatory cyto-
kine IL-10, as described earlier. Interleukin-10 has
been shown to be produced by CD4+ T cells within a
week of commencing bee venom immunotherapy.40
The CD4+ IL-10-positive phenotype is consistent with
the Tr1 regulatory cell subset reported to down-
regulate a pathological immune response in a murine
model of colitis.50
STRATEGY FOR T CELL-TARGETED 
IMMUNOTHERAPY
With the growing appreciation that clinical efficacy of
SIT is associated with an altered T cell response to
allergen, refined allergen preparations that specifically
target allergen-specific T cells are under investigation.
Because only T cell recognition of the preparation is
required, IgE reactivity can be ablated with consequent
improved safety, as well as efficacy, of this approach.
There is a vast literature on the serologic and molecular
characterization of clinically important allergens of dust
mites, pollens, foods and animal dander, although
‘new’ allergens are still being described (e.g. for cat51
and HDM52). The majority have been cloned and
sequenced. Crucial information for the design of new
SIT preparations is the range of dominant T cell epitopes
of major allergens.
Knowledge of T cell-reactive sites of allergen mole-
cules has been slow to emerge because T cell assays are
more cumbersome and technically demanding. Subject
group sizes for these studies have been necessarily
smaller. T cells recognize antigen as small peptides pre-
sented on the surface of antigen-presenting cells, such as
dendritic cells in the context of MHC class II molecules.
Because the frequency of antigen-specific T cells in the
peripheral blood is estimated to be of the order of
1 : 105, the conventional approach to T cell epitope
mapping is to first expand allergen-specific T cells in
culture for 2–3 weeks before testing proliferative and
cytokine responses to nested sets of synthetic peptides
presented by autologous antigen-presenting cells.
Precise identification of the core epitope within
a T cell-reactive peptide requires further testing of
T cell clones with truncated peptide series.53 Critical
MHC anchor and T cell receptor contact residues may
also be identified using single amino acid substituted
peptides.53
Alternatively, algorithms have been devised for pre-
dicting T cell-reactive sites of a molecule based on known
MHC class II restricted peptide motifs. In the case of aller-
gen molecules, this approach has had limited success
and has not always correlated with observed responses
by patient T cells.54 Thus, validation with in vitro T cell
assays is a prerequisite for defining clinically relevant
T cell epitopes.
From studies to date, patterns of T cell reactivity to
allergens are emerging. Importantly, allergens that are
defined as ‘major’ on the basis of specific IgE reactivity
are also major T cell allergens.55 For a particular aller-
gen, T cell epitopes appear to be scattered throughout
the molecule, although regions of high frequency of
reactivity can be found.55–57 Peptides induce a similar
Th2-skewed cytokine profile in atopic donor T cell cul-
tures, as do whole allergen molecules.58 There appears
to be considerable promiscuity of binding of T cell-
reactive peptides to MHC class II molecules: frequencies
of peptide recognition within a population are commonly
as high as 50%.55,58 Thus, limited sets of dominant T cell
epitopes can be selected for targeting a large patient
pool.
Based on a knowledge of dominant T cell epitopes of
an allergen, T cell-targeted strategies for improved SIT
can be devised. These include T cell-reactive peptides or
modified/recombinant allergen molecules that are non-
IgE reactive.
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Peptide immunotherapy
Short T cell-reactive peptides offer considerable advan-
tages for SIT because they are too small to cross-link
cell-bound IgE and, thus, can be given safely at high
doses, with consequent improved efficacy. An alternative
approach for peptide immunotherapy is to use an
altered peptide ligand where a dominant T cell epitope
has been modified by a single amino acid substitution at
a critical T cell receptor contact residue. Altered peptide
ligands for HDM and Japanese cedar pollen allergens
have been found to enhance production of IFN-γ by
T cells compared with the native peptide.59–61
Administration of peptides to downregulate estab-
lished allergic responses has been tested successfully in
several murine models of allergy. Intranasal admini-
stration of 100 µg of a single dominant T cell epitope
peptide of the HDM allergen Der p 1 on 5 consecutive
days could ablate an established T cell response.62
Importantly, tolerance was induced to the entire Der p 1
molecule, as well as to the peptide, with evidence for
intramolecular suppression by the treatment.63 Such
animal studies provided the rationale for performing clin-
ical studies of peptide immunotherapy. The most promis-
ing of these clinical studies has been for bee venom
sensitivity. Increasing doses (1–100 µg) of a mixture of
three T cell epitope peptides of PLA2 were given sub-
cutaneously to a group of five bee venom-allergic
subjects at weekly intervals for 2 months.64 Clinical effi-
cacy was demonstrated by subcutaneous challenge with
PLA2 without systemic allergic symptoms. Only two of the
patients exhibited allergic symptoms to a subsequent bee
sting challenge and these were judged much less severe
than pretreatment reactions. Proliferation and production
of IL-4, IL-5, IL-13 and IFN-γ were decreased in response
to in vitro stimulation with the peptides and PLA2 after
treatment.
The results of clinical trials of cat allergen peptide
immunotherapy have been mixed. An early study using
two large T cell reactive peptides (27 mers) that almost
spanned the chain 1 of Fel d 1 found efficacy only at the
highest dose used (750 µg) and allergic symptoms were
commonly reported from 10 min to 6 h after injection.65
In a subsequent study, Haselden et al. used three smaller
Fel d 1 peptides of 16–17 residues and demonstrated no
evidence of an early IgE-mediated response following
intradermal injection.66 However, nine of 40 patients
treated developed a late asthmatic reaction, apparently
T cell mediated. Follow-up studies using a panel of 12
short overlapping peptides of Fel d 1 demonstrated that
careful up-dosing (starting at 0.1 µg) can inhibit early
and late-phase skin reactions to whole cat dander
without late asthmatic reactions to the peptides.67 This
was associated with decreased peripheral blood mono-
nuclear cell proliferation and production of IL-4, IL-13
and IFN-γ, but increased production of IL-10.
Recombinant allergens for immunotherapy
An alternative strategy for the generation of effective but
hypoallergenic preparations for immunotherapy is to
generate recombinant allergens that have ablated IgE
reactivity but retained dominant T cell epitopes. As for
peptides, these preparations would be easily standard-
ized and could be given at high doses without risk of
IgE-mediated side-effects. Recombinant allergens have
the advantage over individual peptides of providing
multiple T cell epitopes for targeting a larger pool of
reactive T cells. However, more exhaustive testing is
required to establish the relative merits of the two
approaches for particular allergens. An additional
intrinsic advantage of recombinant allergen molecules
that do not bind IgE is that the allergen will be more
likely to be taken up by phagocytosis or endocytosis by
macrophages and dendritic cells and induce Th0/Th1
differentiation of allergen-specific T cells. Immuno-
globulin E-facilitated uptake of natural allergen by
antigen-presenting cells has been shown to drive a
predominantly Th2-type response.68 An earlier approach
to generating hypoallergenic preparations, albeit with
less precision, used chemical treatment, such as by
aldehydes (producing modified allergens termed ‘aller-
goids’).69,70
Different approaches may be taken for genetically
engineering hypoallergenic molecules. In the case of
the major birch pollen allergen Bet v 1, naturally
occurring isoforms with high T cell reactivity but low
or no IgE binding have been identified. These have
been sequenced, cloned and expressed in recombinant
form.71,72 Alternatively, site-directed mutagenesis could
be used to disrupt known IgE-binding epitopes. Targeting
disulfide bonds to disrupt conformational determinants is
an obvious approach that has been successfully applied
in the case of bee venom PLA2,68 Parietaria (Par j 1)73 and
dust mite (Lep d 2)74 allergens. For other allergens, criti-
cal residues for IgE binding can be identified by screening
allergen fragments or synthetic peptides with patient
serum and by ‘alanine scanning’ of peptides. Following
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this approach, hypoallergenic but T cell-reactive aller-
gens have been generated by site-directed mutagenesis
for allergens of birch (Bet v 1),75 peanut (Ara h 3),76
soybean (P34/Gly m Bd)77 and latex (Hev b 5).78
Utilization of recombinant allergens in animal models
of allergy or in clinical studies has, to date, been limited.
Using a mutant protein of Der f 2 (C8/119S) with
reduced IgE binding, Korematsu et al. found more effec-
tive hyposensitization than with native Der f 2 in an
animal model of allergic bronchial asthma.79 The mutant
also induced a strong Th1-type response by cultured
human T cells.
CONCLUDING COMMENTS
Concurrent with developments in the generation of
T cell-reactive hypoallergenic preparations for SIT are
those to improve SIT efficacy based on insight into
underlying mechanisms and factors that influence the
type of cytokines produced by an allergen-activated
T cell in an atopic individual. Such factors include
allergen dose, form and antigen-presenting cell type.
The Th1-inducing adjuvants and DNA vaccines also
show promise for improved efficacy of allergen SIT.80
However, because Th1-type cytokines may play a role in
the pathogenesis of late-phase reactions to allergens
and chronic allergic disease, there should be caution in
merely depolarizing T cell responses. Strategies that
increase the production of anti-inflammatory cytokines,
such as IL-10 and transforming growth factor-β, possibly
mediated by a regulatory T cell subset, are interesting
new approaches. Coupled with these studies are devel-
opments in the delivery of SIT by the more practical and
potentially safe intranasal or oral routes than the current
subcutaneous route. Recent clinical trials of sublingual
SIT are encouraging. Elucidation of mechanisms for
effective SIT will lead not only to wider application of SIT
in clinical practice, but also the design of reliable
laboratory assays for monitoring SIT efficacy.
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